Form D · Pharmaceuticals
Boston Biopharma, Inc.
Roswell, GA · CIK 0001857036
Offering snapshot reported Apr 29, 2021 · SEC filing
- Reported sold
- $1.52M Indefinite offering
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 29, 2021 | Initial | $1,515,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-397638
Source: Form D, filed Apr 29, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Terry Kevin Clark | Director |
| Ahmad Hashem | Director, Executive |
| Ammar Hemaidan | Director |
| Peter Gerhard Wodtke | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
570 Colonial Park Drive, Suite 309
Roswell, GA, 30075
Roswell, GA, 30075